Immunai
Peripheral Tissue Analysis
StartupImmunai is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2019. Peripheral Tissue Analysis. The company has raised a total of $295M across 3 funding rounds, currently at the B stage. Immunai was founded by Noam Solomon and Luis Voloch. Key investors include Koch Disruptive Technologies, ICON, 8VC, among 14 total investors. The company has 51-200 employees. Core technologies: Artificial Intelligence, Deep Learning, Machine Learning.
With $295M in total funding, Immunai is a B-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D.
- StageB
- ProductR&D
- ModelB2B
- Employees51-200
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$215M
- Koch Disruptive TechnologiesLead
- ICON
- 8VC
14 investors total
Noam SolomonCo-founder & CEO
Luis VolochCo-founder & CTO
13 articles covered by sources including www.calcalistech.com,
en.globes.co.il,
techcrunch.com,
www.startupticker.ch,
www.israel21c.org.
What does Immunai do?
Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease. The platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
How much funding has Immunai raised?
Immunai has raised $295M in total funding across 3 rounds. The company is currently at the B stage. Key investors include Koch Disruptive Technologies, ICON, 8VC.
Who founded Immunai?
Immunai was founded in 2019 by Noam Solomon (Co-founder & CEO), Luis Voloch (Co-founder & CTO).
What sector is Immunai in?
Immunai operates in Business Software, IT, R&D & Data Solutions, Data Analysis & Decision Support, Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Artificial Intelligence, Deep Learning, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories, Providers, Life Sciences, Pharmaceuticals.
Where is Immunai located?
Immunai is based in Tel Aviv, Israel, Center District. The company also has offices abroad.